On 3 May 2019 Health Canada released the new Guidance Document: Regulatory Requirements for Drug Identification Numbers. The guidance document provides "assistance on the interpretation of the regulatory requirements associated with a [drug identification number]", as well as "guidance to manufacturers on their obligation to accurately report to Health Canada [certain] notifications for a change of drug status". This particular guidance document replaces a number of Health Canada documents, including the following:

  • Guidance Document: Cancellation of a Drug Identification Number and Notification of Discontinuation of Sales; and
  • Issuance of Drug Identification Numbers for New Drugs.

This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.